1415797-80-6

Basic information

• Product Name: ethyl 5-(2-(2-(tert-butyldiphenylsilyloxo)ethyl)phenylamino)thiazole-4-formate
• Synonyms: ethyl 5-(2-(2-(tert-butyldiphenylsilyloxo)ethyl)phenylamino)thiazole-4-formate
• CAS NO: 1415797-80-6
• Molecular Weight: 530.763
• Mol File: 1415797-80-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: ethyl 5-(2-(2-(tert-butyldiphenylsilyloxo)ethyl)phenylamino)thiazole-4-formate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 5-(2-(2-(tert-butyldiphenylsilyloxo)ethyl)phenylamino)thiazole-4-formate(1415797-80-6)
• EPA Substance Registry System: ethyl 5-(2-(2-(tert-butyldiphenylsilyloxo)ethyl)phenylamino)thiazole-4-formate(1415797-80-6)

Safety Data

• Hazardous Substances Data: 1415797-80-6(Hazardous Substances Data)

Upstream product

• 931105-21-4 2-tert-butyldiphenylsilyloxyethylaniline 
• 2999-46-4 Ethyl isocyanoacetate 
• 1415797-79-3 2-tert-butyldiphenylsilyloxyethylphenyl isothiocyanate 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 5339-85-5 2-aminophenethyl alcohol 

Downstream Products

• 1415797-81-7 ethyl 5-(2-(2-(tert-butyldiphenylsilyloxo)ethyl)phenyl-2-methoxycarbonylacetamido)thiazole-4-formate 
• 1415797-82-8 4-(2-(2-(tert-butyldiphenylsilyloxy)ethyl)phenyl)-6-(methoxycarbonyl)-5-oxo-4,5-dihydro-thiazolo[5,4-b]pyridine-7-oxy sodium salt 
• 1415797-84-0 methyl 4-(2-(2-(tert-butyldiphenylsilyloxy)ethyl)phenyl)-5-oxo-4,5-dihydrothiazolo[5,4-b]pyridine-6-formate 
• 1415797-85-1 4-(2-(2-(tert-butyldiphenylsilyloxy)ethyl)phenyl)-5-oxo-4,5-dihydrothiazolo[5,4-b]pyridine-6-formic acid 
• 1415798-29-6 N-(4-(2-aminopyridine-4-oxy)-3-fluorophenyl)-4-(2-(2-hydroxyethyl)phenyl)-5-oxo-4,5-dihydrothiazolo[5,4-b]pyridine-6-formamide 
• 1415797-83-9 C₃₃H₃₁F₃N₂O₇S₂Si 
• 1415797-86-2 C₄₂H₃₈FN₅O₄SSi 

Relevant articles and documents

HETEROCYCLIC PYRIDONE COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF

The present invention relates to a heterocyclic pyridone compound represented by General Formula (I), where the heterocyclic pyridone compound is used as a tyrosine kinase inhibitor, and particularly a c-Met inhibitor. The present invention also relates to intermediates for preparing heterocyclic pyridone compound and a preparation method. The present invention further relates to a pharmaceutical composition containing the heterocyclic pyridone compound as an active ingredient, and a use of the pharmaceutical composition in treatment of diseases associated with tyrosine kinase c-Met, especially cancer associated with c-Met, as a medicament.